The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Hanauer, Stephen
Item TypeName
Concept Gastrointestinal Agents
Academic Article Cyclosporin for severe ulcerative colitis: a user's guide.
Academic Article Comparative tolerability of treatments for inflammatory bowel disease.
Academic Article Infliximab in Crohn's disease: first anniversary clinical experience.
Academic Article Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Academic Article Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
Academic Article Evolutionary biologic therapy for inflammatory bowel disease.
Academic Article Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
Academic Article Immunogenicity of infliximab in Crohn's disease.
Academic Article Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Academic Article Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Academic Article Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Academic Article Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Academic Article Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
Academic Article Safety first: messages from Digestive Disease Week 2006.
Academic Article Emerging biologic therapies in inflammatory bowel disease.
Academic Article Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Academic Article Moving ahead or falling behind?
Academic Article The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Academic Article Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Academic Article Controversies with aminosalicylates in inflammatory bowel disease.
Academic Article Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Academic Article Management of Crohn's disease in adults.
Academic Article Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Academic Article General principles and pharmacology of biologics in inflammatory bowel disease.
Academic Article Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Academic Article European evidence-based consensus on the diagnosis and management of Crohn's disease.
Academic Article The expanding role of biologic therapy for IBD.
Academic Article Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Academic Article An evidence-based systematic review on medical therapies for inflammatory bowel disease.
Academic Article Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.
Academic Article Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Academic Article Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Academic Article Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Academic Article Practical application of anti-TNF therapy for luminal Crohn's disease.
Academic Article What to take from TREAT?
Academic Article The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
Academic Article Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Academic Article Review article: safety of infliximab in clinical trials.
Academic Article A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Academic Article Infliximab or cyclosporine for severe ulcerative colitis.
Academic Article Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies.
Academic Article AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study.
Academic Article Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Academic Article Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
Academic Article Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Academic Article Aminosalicylates for induction of remission or response in Crohn's disease.
Academic Article Optimizing pharmacologic management of inflammatory bowel disease.
Academic Article Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Academic Article Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Academic Article Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
Academic Article Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Academic Article Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Search Criteria
  • Gastrointestinal Agents